Heron Therapeuti Net Income
| HRTX Stock | USD 1.15 0.02 1.71% |
As of the 16th of February 2026, Heron Therapeuti retains the Downside Deviation of 3.73, market risk adjusted performance of 0.081, and Risk Adjusted Performance of 0.034. Heron Therapeuti technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Heron Therapeuti Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.9639 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -12.2 M | -12.8 M | |
| Net Loss | -163.8 M | -172 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Net Loss | (0.08) | (0.08) | |
| Net Income Per E B T | 1.10 | 0.91 |
Heron | Net Income | Build AI portfolio with Heron Stock |
The evolution of Net Income for Heron Therapeuti provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Heron Therapeuti compares to historical norms and industry peers.
Latest Heron Therapeuti's Net Income Growth Pattern
Below is the plot of the Net Income of Heron Therapeuti over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Heron Therapeuti financial statement analysis. It represents the amount of money remaining after all of Heron Therapeuti operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Heron Therapeuti's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Heron Therapeuti's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (13.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Heron Net Income Regression Statistics
| Arithmetic Mean | (102,836,594) | |
| Coefficient Of Variation | (80.91) | |
| Mean Deviation | 72,787,206 | |
| Median | (97,591,000) | |
| Standard Deviation | 83,207,850 | |
| Sample Variance | 6923.5T | |
| Range | 220.6M | |
| R-Value | (0.15) | |
| Mean Square Error | 7223.2T | |
| R-Squared | 0.02 | |
| Significance | 0.57 | |
| Slope | (2,440,056) | |
| Total Sum of Squares | 110776.7T |
Heron Net Income History
Other Fundumenentals of Heron Therapeuti
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Heron Therapeuti Net Income component correlations
Heron Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Heron Therapeuti is extremely important. It helps to project a fair market value of Heron Stock properly, considering its historical fundamentals such as Net Income. Since Heron Therapeuti's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Heron Therapeuti's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Heron Therapeuti's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeuti. Market participants price Heron higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Heron Therapeuti assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth 0.165 | Return On Assets | Return On Equity |
The market value of Heron Therapeuti is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeuti's value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeuti's market value can be influenced by many factors that don't directly affect Heron Therapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heron Therapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Heron Therapeuti's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Heron Therapeuti 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Heron Therapeuti's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Heron Therapeuti.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Heron Therapeuti on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Heron Therapeuti or generate 0.0% return on investment in Heron Therapeuti over 90 days. Heron Therapeuti is related to or competes with NeOnc Technologies, Invivyd, Protara Therapeutics, Sellas Life, Mediwound, Protalix Biotherapeutics, and Coherus BioSciences. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs More
Heron Therapeuti Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Heron Therapeuti's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Heron Therapeuti upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.73 | |||
| Information Ratio | 0.0127 | |||
| Maximum Drawdown | 17.78 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.6 |
Heron Therapeuti Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Heron Therapeuti's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Heron Therapeuti's standard deviation. In reality, there are many statistical measures that can use Heron Therapeuti historical prices to predict the future Heron Therapeuti's volatility.| Risk Adjusted Performance | 0.034 | |||
| Jensen Alpha | 0.0163 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.012 | |||
| Treynor Ratio | 0.071 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Heron Therapeuti's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Heron Therapeuti February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.034 | |||
| Market Risk Adjusted Performance | 0.081 | |||
| Mean Deviation | 2.61 | |||
| Semi Deviation | 3.12 | |||
| Downside Deviation | 3.73 | |||
| Coefficient Of Variation | 3071.08 | |||
| Standard Deviation | 3.52 | |||
| Variance | 12.41 | |||
| Information Ratio | 0.0127 | |||
| Jensen Alpha | 0.0163 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.012 | |||
| Treynor Ratio | 0.071 | |||
| Maximum Drawdown | 17.78 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.6 | |||
| Downside Variance | 13.9 | |||
| Semi Variance | 9.76 | |||
| Expected Short fall | (3.31) | |||
| Skewness | 0.071 | |||
| Kurtosis | 0.7194 |
Heron Therapeuti Backtested Returns
At this stage we consider Heron Stock to be very risky. Heron Therapeuti holds Efficiency (Sharpe) Ratio of 0.0297, which attests that the entity had a 0.0297 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Heron Therapeuti, which you can use to evaluate the volatility of the firm. Please check out Heron Therapeuti's Downside Deviation of 3.73, risk adjusted performance of 0.034, and Market Risk Adjusted Performance of 0.081 to validate if the risk estimate we provide is consistent with the expected return of 0.11%. Heron Therapeuti has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.48, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Heron Therapeuti will likely underperform. Heron Therapeuti right now retains a risk of 3.56%. Please check out Heron Therapeuti potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Heron Therapeuti will be following its current trending patterns.
Auto-correlation | -0.01 |
Very weak reverse predictability
Heron Therapeuti has very weak reverse predictability. Overlapping area represents the amount of predictability between Heron Therapeuti time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Heron Therapeuti price movement. The serial correlation of -0.01 indicates that just 1.0% of current Heron Therapeuti price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.01 | |
| Spearman Rank Test | -0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Heron Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Heron Therapeuti reported net income of (13.58 Million). This is 103.98% lower than that of the Biotechnology sector and 119.39% lower than that of the Health Care industry. The net income for all United States stocks is 102.38% higher than that of the company.
Heron Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Heron Therapeuti's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Heron Therapeuti could also be used in its relative valuation, which is a method of valuing Heron Therapeuti by comparing valuation metrics of similar companies.Heron Therapeuti is currently under evaluation in net income category among its peers.
Heron Therapeuti Institutional Holders
Institutional Holdings refers to the ownership stake in Heron Therapeuti that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Heron Therapeuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Heron Therapeuti's value.| Shares | Aigh Capital Management, Llc | 2025-06-30 | 3 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 2.9 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.9 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.8 M | Renaissance Technologies Corp | 2025-06-30 | 2.7 M | Jw Asset Management, Llc | 2025-06-30 | 2.3 M | Congress Park Capital Llc | 2025-06-30 | 2.3 M | Citadel Advisors Llc | 2025-06-30 | 2.2 M | Tang Capital Management Llc | 2025-06-30 | 2.1 M | Rubric Capital Management Lp | 2025-06-30 | 26.7 M | Blackrock Inc | 2025-06-30 | 10.1 M |
Heron Fundamentals
| Return On Equity | -24.09 | ||||
| Return On Asset | 0.0043 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 304.6 M | ||||
| Shares Outstanding | 183.36 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 83.44 % | ||||
| Number Of Shares Shorted | 35.26 M | ||||
| Price To Earning | (5.15) X | ||||
| Price To Book | 30.16 X | ||||
| Price To Sales | 1.36 X | ||||
| Revenue | 144.28 M | ||||
| Gross Profit | 102.78 M | ||||
| EBITDA | (5.06 M) | ||||
| Net Income | (13.58 M) | ||||
| Cash And Equivalents | 83.54 M | ||||
| Cash Per Share | 0.81 X | ||||
| Total Debt | 177.76 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.77 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (22.53 M) | ||||
| Short Ratio | 21.75 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Price To Earnings To Growth | (0.18) X | ||||
| Target Price | 4.33 | ||||
| Number Of Employees | 122 | ||||
| Beta | 1.25 | ||||
| Market Capitalization | 210.87 M | ||||
| Total Asset | 233.15 M | ||||
| Retained Earnings | (1.92 B) | ||||
| Working Capital | 117.56 M | ||||
| Current Asset | 134.75 M | ||||
| Current Liabilities | 19.73 M | ||||
| Net Asset | 233.15 M |
About Heron Therapeuti Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heron Therapeuti's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heron Therapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heron Therapeuti based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.